 The vaccine development against Mycobacterium tuberculosis is in pre-clinical stage, against HIV-1 it reached phase II clinical trial and against RSV it is in phase I. Fudan University in collaboration with ID Pharma Co. Ltd. is engaged in development of the vaccine for COVID-19 prevention.SeV serves as a vaccine backbone vector in the project .SeV replication occurs exclusively in the cytoplasm of the host cell.